Other News To Note
Wednesday, January 18, 2012
Cellceutix Corp., of Beverly, Mass., said preclinical research into the mechanism of action of Kevetrin showed that the drug not only activates p53 but targets HDAC2. Kevetrin down-regulated HDAC2 in mutant and null p53 cancer cell lines. Clinical trials in cancer are expected to start this year.
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.